DelveInsight's newly released automated suturing devices research report - forecast till 2030 paints a picture of a maturing but still-expanding industry. From a base of USD 2.53 billion in 2023, the market is on track to grow at a CAGR of 6.81%, reaching an estimated USD 3.74 billion by the close of the decade. The trajectory reflects a broader shift in how surgical teams think about closure — less about tradition, more about repeatability and speed.
An automatic suture device, in practical terms, takes a task that once relied heavily on individual surgeon skill and turns it into something more consistent and faster to execute. That shift matters across cardiovascular, gastrointestinal, orthopedic, and gynecological surgery, and it's a big reason the broader automated suturing devices market keeps attracting capital and clinical interest alike.
The Numbers Behind the Demand
It starts with disease burden. WHO's 2022 figures show breast cancer topping the list of new diagnoses at 2.26 million cases in 2020, with lung, colorectal, and prostate cancers not far behind. Every one of those diagnoses eventually funnels into a surgical schedule somewhere, and that pipeline is a core driver behind the automated suturing devices category's steady climb.
Trauma adds a second, less-discussed layer. The WHO estimates 20 to 50 million people are affected by non-fatal injuries annually worldwide, a portion of which lead to permanent disability. The International Labour Organization separately tallies around 340 million workplace accidents each year. None of this is glamorous, but it's foundational to the demand curve running through the endoluminal suturing devices market and similar niches.
Regulatory clearances have kept the innovation pipeline moving. Endo Tools Therapeutics received FDA sign-off for its Endomina platform in January 2022, enabling endoscopic suturing inside the gastrointestinal tract. Not long before that, in mid-2021, Anchora Medical earned 510(k) clearance for its Su2ura Approximation Device, built for laparoscopic soft-tissue closure. Each approval chips away at the boundary of what automated technology can realistically replace.
Friction Points to Note
The runway isn't entirely clear, though. A thin bench of clinicians trained on newer automated systems, spotty device availability in some markets, and a price gap versus traditional sutures all slow adoption in places. Elective procedure volumes also took a hit during the pandemic, a dip the industry has since largely recovered from.
Segments Carrying the Weight
Gynecological surgery stands out as a particularly strong contributor. WHO data cites nearly 604,000 new cervical cancer cases globally in 2020, with ovarian and endometrial cancers adding hundreds of thousands more diagnoses on top of that. This volume feeds meaningfully into the gynecology suture market, positioning it as one of the steadier growth pockets through 2030.
On geography, North America remains the anchor region. U.S. surgical activity topped 13 million procedures between January 2019 and January 2021 per WHO figures, alongside nearly 55.4 million motor-vehicle-related injuries recorded in 2020. With CDC data showing six in ten American adults managing at least one chronic condition, the us automated suturing devices market is well positioned to keep its lead, with knock-on benefits for the adjacent us wound closure devices market as well.
Companies shaping the competitive landscape include Medtronic, LSI Solutions, Sutrue Limited, Apollo Endosurgery, B. Braun Melsungen AG, Becton, Dickinson & Company, Ethicon (Johnson & Johnson), Smith & Nephew, EndoEvolution, Mellon Medical B.V., Endo Tools Therapeutics, EDGe Surgical, Medical Microinstruments, and SuturTek, among others.
What Comes Next
As clinical trust builds and regulatory pathways continue to open up, the industry's outlook through 2030 looks solid rather than spectacular — steady, procedure-driven growth rather than a sudden breakout. Readers interested in the wider picture can also explore DelveInsight's analysis of the suture anchor device market, the cardiac sutures market, and the united states surgical sutures market, each closely tied to this broader wound closure ecosystem.
Latest Reports Offered by Delveinsight
congenital hyperinsulinism market | corneal ulcer market | cyclin-dependent kinase-like 5 deficiency disorder | diabetic gastroparesis market | diabetic ketoacidosis market | diabetic peripheral neuropathy market | diagnostic imaging equipment market | dyslipidemia market | dystrophic epidermolysis bullosa market | eosinophilia market | eosinophilic gastroenteritis market | esophageal cancer market | exophthalmos market | facioscapulohumeral muscular dystrophy market | familial adenomatous polyposis market | fatty acid oxidation disorders market | female infertility market | fertility monitoring devices market | fgfr market | gastroesophageal reflux disease market | genital herpes market | geographic atrophy market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
Comments